The stock of Chiasma Inc (NASDAQ:CHMA) hit a new 52-week low and has $2.09 target or 13.00% below today’s $2.40 share price. The 8 months bearish chart indicates high risk for the $57.10M company. The 1-year low was reported on Oct, 28 by Barchart.com. If the $2.09 price target is reached, the company will be worth $7.42 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 53,921 shares traded hands. Chiasma Inc (NASDAQ:CHMA) has declined 68.73% since March 28, 2016 and is downtrending. It has underperformed by 73.45% the S&P500.
Analysts await Chiasma Inc (NASDAQ:CHMA) to report earnings on November, 10. They expect $-0.66 earnings per share, down 43.48% or $0.20 from last year’s $-0.46 per share. After $-0.83 actual earnings per share reported by Chiasma Inc for the previous quarter, Wall Street now forecasts -20.48% EPS growth.
Chiasma Inc (NASDAQ:CHMA) Ratings Coverage
Out of 3 analysts covering Chiasma (NASDAQ:CHMA), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Chiasma has been the topic of 5 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by William Blair on Monday, August 10. The rating was downgraded by Barclays Capital on Monday, April 25 to “Equal-Weight”. William Blair downgraded Chiasma Inc (NASDAQ:CHMA) on Monday, April 18 to “Market Perform” rating. The firm has “Outperform” rating by Cowen & Co given on Monday, August 10. Barclays Capital initiated it with “Overweight” rating and $40 target price in Monday, August 10 report.
According to Zacks Investment Research, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA.”
More notable recent Chiasma Inc (NASDAQ:CHMA) news were published by: Marketwatch.com which released: “Chiasma’s stock plummets 54% premarket after FDA response letter” on June 18, 2015, also Prnewswire.com with their article: “Chiasma, Inc. Prices Initial Public Offering of Common Stock” published on July 15, 2015, Quotes.Wsj.com published: “Chiasma Inc. CHMA (US: Nasdaq)” on July 10, 2015. More interesting news about Chiasma Inc (NASDAQ:CHMA) were released by: Marketwatch.com and their article: “Chiasma to cut one-third of its workforce as part of restructuring” published on June 14, 2016 as well as Streetinsider.com‘s news article titled: “Form 4 CHIASMA, INC For: Oct 25 Filed by: Fitzpatrick Mark J.” with publication date: October 26, 2016.
CHMA Company Profile
Chiasma, Inc., incorporated on April 12, 2001, is a biopharmaceutical company. The Firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Firm has completed a Phase III clinical trial of its TPE platform product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.